SE503191C2 - Farmaceutisk komposition innehållande en somatostatinanalog samt användning därav - Google Patents

Farmaceutisk komposition innehållande en somatostatinanalog samt användning därav

Info

Publication number
SE503191C2
SE503191C2 SE8802569A SE8802569A SE503191C2 SE 503191 C2 SE503191 C2 SE 503191C2 SE 8802569 A SE8802569 A SE 8802569A SE 8802569 A SE8802569 A SE 8802569A SE 503191 C2 SE503191 C2 SE 503191C2
Authority
SE
Sweden
Prior art keywords
alkyl
hydrogen
lys
alkoxy
amino
Prior art date
Application number
SE8802569A
Other languages
English (en)
Swedish (sv)
Other versions
SE8802569L (sv
SE8802569D0 (sv
Inventor
Thomas Cavanak
Allan Harris
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878716324A external-priority patent/GB8716324D0/en
Priority claimed from GB878716326A external-priority patent/GB8716326D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of SE8802569D0 publication Critical patent/SE8802569D0/xx
Publication of SE8802569L publication Critical patent/SE8802569L/xx
Publication of SE503191C2 publication Critical patent/SE503191C2/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/16—Somatostatin; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SE8802569A 1987-07-10 1988-07-08 Farmaceutisk komposition innehållande en somatostatinanalog samt användning därav SE503191C2 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB878716324A GB8716324D0 (en) 1987-07-10 1987-07-10 Organic compounds
GB878716326A GB8716326D0 (en) 1987-07-10 1987-07-10 Organic compounds

Publications (3)

Publication Number Publication Date
SE8802569D0 SE8802569D0 (sv) 1988-07-08
SE8802569L SE8802569L (sv) 1989-01-11
SE503191C2 true SE503191C2 (sv) 1996-04-15

Family

ID=26292476

Family Applications (2)

Application Number Title Priority Date Filing Date
SE8802569A SE503191C2 (sv) 1987-07-10 1988-07-08 Farmaceutisk komposition innehållande en somatostatinanalog samt användning därav
SE9301290A SE9301290A0 (sv) 1987-07-10 1993-04-20 Användning av en somatostatinanalog

Family Applications After (1)

Application Number Title Priority Date Filing Date
SE9301290A SE9301290A0 (sv) 1987-07-10 1993-04-20 Användning av en somatostatinanalog

Country Status (27)

Country Link
US (2) US5753618A (fi)
JP (1) JP2578477B2 (fi)
AU (1) AU618270B2 (fi)
BE (1) BE1001079A4 (fi)
CA (1) CA1328402C (fi)
CH (1) CH677449A5 (fi)
CS (1) CS411591A3 (fi)
CY (2) CY1631A (fi)
DE (2) DE3845000C2 (fi)
DK (2) DK174125B1 (fi)
ES (1) ES2010561A6 (fi)
FI (1) FI93308C (fi)
FR (1) FR2617714B1 (fi)
GB (1) GB2208200B (fi)
GR (1) GR1000172B (fi)
HK (1) HK16492A (fi)
HU (1) HU203480B (fi)
IE (1) IE61908B1 (fi)
IL (1) IL87044A0 (fi)
LU (1) LU87268A1 (fi)
MY (2) MY103746A (fi)
NL (1) NL194823C (fi)
NO (1) NO179359C (fi)
NZ (1) NZ225340A (fi)
PT (1) PT87957B (fi)
SE (2) SE503191C2 (fi)
SG (1) SG3692G (fi)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813339D0 (en) * 1988-06-06 1988-07-13 Sandoz Ltd Improvements in/relating to organic compounds
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5626945A (en) * 1993-09-28 1997-05-06 International Paper Company Repulpable, water repellant paperboard
US6355613B1 (en) * 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
WO1998008528A1 (en) 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
ES2167189B1 (es) * 1999-12-17 2003-04-01 Lipotec Sa Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos
US6316414B1 (en) 2000-07-31 2001-11-13 Dabur Research Foundation Somatostatin analogs for the treatment of cancer
WO2002100888A1 (en) * 2001-06-08 2002-12-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Somatostatin-dopamine chimeric analogs
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
US20030207811A1 (en) * 2002-05-03 2003-11-06 Schrier Bruce K. Method of treating retinopathy of prematurity using somatostatin analogs
ATE549011T1 (de) 2005-11-10 2012-03-15 Chemi Spa Formulierungen mit verzögerter freisetzung, die somatostatin-analoge wachstumshormoninhibitoren enthalten
ES2444890T3 (es) * 2006-03-31 2014-02-27 Erasmus University Medical Center Rotterdam Nueva composición para el control del crecimiento tumoral
US20100160275A1 (en) * 2006-09-26 2010-06-24 Lee Eva Y H P Methods and compositions for cancer prevention and treatment
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
US20090325863A1 (en) * 2008-06-13 2009-12-31 Kleinberg David L Somatostatin analogs and IGF-I inhibition for breast cancer prevention
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
US8629103B2 (en) * 2010-12-02 2014-01-14 New York University Treatment of non-proliferative cystic disease of the breast
CN103732239A (zh) * 2011-06-02 2014-04-16 加利福尼亚大学董事会 利用θ-防御素的炎性蛋白酶的阻断
CN104768565B (zh) 2012-11-01 2017-04-26 益普生制药股份有限公司 促生长素抑制素类似物及其二聚体
TWI523863B (zh) 2012-11-01 2016-03-01 艾普森藥品公司 體抑素－多巴胺嵌合體類似物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621770A5 (en) * 1976-02-23 1981-02-27 Sandoz Ag Process for the preparation of novel peptide compounds
EP0000053B1 (en) * 1977-06-08 1981-05-27 Merck & Co. Inc. Somatostatin analogs, process for their preparation and pharmaceutical compositions containing them
LU78191A1 (de) * 1977-09-28 1979-05-25 Ciba Geigy Ag Verfahren zur herstellung von neuen cyclopeptiden
US4328214A (en) * 1979-07-04 1982-05-04 Ciba-Geigy Corporation Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture
US4900730A (en) * 1981-01-14 1990-02-13 Toyo Jozo Co., Ltd. Preparation which promotes the absorption of peptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS57188526A (en) * 1981-05-14 1982-11-19 Takeda Chem Ind Ltd Peptide-containing pharmaceutical preparation
US4374060A (en) * 1981-07-15 1983-02-15 Merck & Co., Inc. Process for the preparation of cyclic hexapeptide
EP0083305B1 (de) * 1981-12-24 1985-07-10 Ciba-Geigy Ag Cyclische Octapeptide und pharmazeutische Präparate davon, sowie Verfahren zur Herstellung derselben und ihre Anwendung
US4522813A (en) * 1983-10-27 1985-06-11 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
CH666035A5 (de) * 1984-12-24 1988-06-30 Sandoz Ag 8-alpha-acylaminoergolene.
US4650787A (en) * 1985-04-25 1987-03-17 Schally Andrew Victor Biologically active octapeptides
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
JPH085913B2 (ja) * 1985-09-12 1996-01-24 ザ・アドミニストレ−タ−ズ・オブ・ザ・ツ−レイン・エデユケイシヨナル・フアンド 治療用ソマトスタチン同族体
GR862206B (en) * 1985-09-12 1986-12-31 Univ Tulane Therapeutic somatostatin analogs
NL8701143A (nl) * 1986-05-27 1987-12-16 Sandoz Ag Farmaceutische preparaten.
HU906340D0 (en) * 1986-10-13 1991-04-29 Sandoz Ag Synthesis in solid phase for producing peptonic alcohols
AU639371B2 (en) * 1987-07-10 1993-07-22 Novartis Ag Method of treating breast cancer
US5187150A (en) * 1987-10-14 1993-02-16 Debiopharm S.A. Polyester-based composition for the controlled release of polypeptide medicinal substances
AU2284588A (en) * 1988-09-26 1990-03-29 Sandoz Ltd. Improvements in or relating to organic compounds
MY106120A (en) * 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
US5384309A (en) * 1989-07-17 1995-01-24 Genentech, Inc. Cyclized peptides and their use as platelet aggregation inhibitors
JPH0532696A (ja) * 1990-09-28 1993-02-09 Takeda Chem Ind Ltd 副甲状腺ホルモン誘導体

Also Published As

Publication number Publication date
FI93308B (fi) 1994-12-15
MY109309A (en) 1997-01-31
PT87957A (pt) 1989-06-30
SG3692G (en) 1992-03-20
IL87044A0 (en) 1988-12-30
JPS6431728A (en) 1989-02-02
HUT47865A (en) 1989-04-28
DK385488A (da) 1989-01-11
GB2208200A (en) 1989-03-15
JP2764041B2 (ja) 1998-06-11
FI93308C (fi) 1995-03-27
NL194823B (nl) 2002-12-02
SE8802569L (sv) 1989-01-11
MY103746A (en) 1993-09-30
CH677449A5 (fi) 1991-05-31
CA1328402C (en) 1994-04-12
NO179359B (no) 1996-06-17
ES2010561A6 (es) 1989-11-16
PT87957B (pt) 1995-03-01
IE882091L (en) 1989-01-10
HU203480B (en) 1991-08-28
NL8801734A (nl) 1989-02-01
AU618270B2 (en) 1991-12-19
AU1889388A (en) 1989-01-12
NL194823C (nl) 2003-04-03
CY1632A (en) 1992-07-10
NO883054D0 (no) 1988-07-08
DK174476B1 (da) 2003-04-14
IE61908B1 (en) 1994-11-30
JP2578477B2 (ja) 1997-02-05
JPH0748272A (ja) 1995-02-21
CS411591A3 (en) 1992-06-17
DE3845000C2 (de) 1998-11-19
GR880100458A (en) 1989-04-12
DE3822557C2 (de) 1998-07-02
NZ225340A (en) 1991-05-28
DK174125B1 (da) 2002-07-01
DK200100558A (da) 2001-04-04
LU87268A1 (fr) 1989-03-08
SE9301290D0 (sv) 1993-04-20
FR2617714A1 (fr) 1989-01-13
SE8802569D0 (sv) 1988-07-08
SE9301290A0 (sv) 1993-04-20
NO883054L (no) 1989-01-11
DE3822557A1 (de) 1989-01-19
CY1631A (en) 1992-07-10
GR1000172B (el) 1991-11-15
FR2617714B1 (fr) 1991-09-20
HK16492A (en) 1992-03-06
FI883261A0 (fi) 1988-07-08
US6066616A (en) 2000-05-23
FI883261A (fi) 1989-01-11
DK385488D0 (da) 1988-07-08
US5753618A (en) 1998-05-19
GB8816024D0 (en) 1988-08-10
NO179359C (no) 1996-09-25
BE1001079A4 (fr) 1989-07-04
GB2208200B (en) 1991-11-27

Similar Documents

Publication Publication Date Title
SE503191C2 (sv) Farmaceutisk komposition innehållande en somatostatinanalog samt användning därav
US4725577A (en) Biologically active lysine containing octapeptides
CA2218616C (en) Nitrosylated neuropeptides
JP3784418B2 (ja) ソマトスタチン類似体およびラパマイシンの配合
US9149510B2 (en) Combinations of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes
LAMBERTS et al. Studies on the mechanism of action of the inhibitory effect of the somatostatin analog SMS 201–995 on the growth of the prolactin/adrenocorticotropin-secreting pituitary tumor 7315a
US5145837A (en) Treatment of arthritis
Ferland et al. Inhibition by six somatostatin analogs of plasma growth hormone levels stimulated by thiamylal and morphine in the rat
Ellison et al. Characterization of the in vivo and in vitro inhibition of gastrin secretion from gastrinoma by a somatostatin analogue (SMS 201-995)
KR100195894B1 (ko) 소마토스타틴 동족체를 함유하는 약학 조성물
GB2239178A (en) Somatostatin analogues for the treatment of breast cancer
JP2764041B6 (ja) ソマトスタチン類に関する改良
EP1040837A2 (en) Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder
WO2002009739A1 (en) Treatment of ocular disorders with somatostatin analogues
Petersenn Efficacy and limits of somatostatin analogs
CA2263042A1 (en) Treatment of edema
Haddock et al. The effect of the somatostatin analogue SMS 201-995 on experimental pancreatic carcinogenesis in the Syrian golden hamster

Legal Events

Date Code Title Description
NUG Patent has lapsed